ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
08 Janvier 2024 - 7:23PM
Business Wire
- Appointment of Dr. Rob Scott, former Chief Medical Officer
and Head of Development at AbbVie, where he oversaw successful drug
development for brands like Skyrizi, and Rinvoq
- Dr. Rob Scott brings extensive clinical development and
regulatory experience to ABIONYX Pharma
Access here the full press release
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME
eligible), a next-generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world's only recombinant apoA-I, is pleased to announce the
appointment of Dr. Rob Scott as Chief Medical Officer and Head of
R&D with immediate effect.
Cyrille Tupin, CEO of ABIONYX Pharma, commented: "We are
excited to welcome Rob to our team just before the start of the
J.P. Morgan Healthcare annual conference in San Francisco. As we
develop our portfolio of clinical stage assets based on our unique
apoA-I platform, Rob will bring us a wealth of experience to
accelerate our programs. I look forward to working with Rob to
transform ABIONYX Pharma into a successful biotech company focused
on sepsis and other critical indications based on the only
recombinant apoA-I in the industry."
Dr. Rob Scott commented: "I am delighted to be joining
this next generation biotech, especially at a time of great
momentum with the Company's latest outstanding Phase 2a results in
sepsis. I look forward to working with the team to design and
execute the pivotal approval program as ABIONYX continues to
advance its exciting biodrug candidate through the clinical
development and partnership process."
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240108409097/en/
NewCap. Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53 NewCap.
Media relations Arthur Rouillé abionyx@newcap.eu +33 (0)1 44 71 00
15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
